NO984418L - Arylaminokondenserte pyridiner og pyrimidiner - Google Patents

Arylaminokondenserte pyridiner og pyrimidiner

Info

Publication number
NO984418L
NO984418L NO984418A NO984418A NO984418L NO 984418 L NO984418 L NO 984418L NO 984418 A NO984418 A NO 984418A NO 984418 A NO984418 A NO 984418A NO 984418 L NO984418 L NO 984418L
Authority
NO
Norway
Prior art keywords
arylamino
pyrimidines
condensed pyridines
pyridines
condensed
Prior art date
Application number
NO984418A
Other languages
English (en)
Other versions
NO984418D0 (no
Inventor
Rajagopal Bakthavatchalam
Argyrios Georgios Arvanitis
James Peter Beck
Gary Avonn Cain
Robert John Chorvat
Paul Joseph Gilligan
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NO984418D0 publication Critical patent/NO984418D0/no
Publication of NO984418L publication Critical patent/NO984418L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det er beskrevet kortikotropinfrigivende faktor (CRF) antagonister av formlene (1) eller formel (II); videre er det beskrevet anvendelse av forbindelsene for behandling av angst, depresjon og andre psykiatriske og neurologiske sykdomstilstander.
NO984418A 1996-03-27 1998-09-22 Arylaminokondenserte pyridiner og pyrimidiner NO984418L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1415796P 1996-03-27 1996-03-27
US64661296A 1996-05-08 1996-05-08
US3053696P 1996-10-31 1996-10-31
US3912497P 1997-02-25 1997-02-25
PCT/US1997/004852 WO1997035539A2 (en) 1996-03-27 1997-03-25 Arylamino fused pyridines and pyrimidines

Publications (2)

Publication Number Publication Date
NO984418D0 NO984418D0 (no) 1998-09-22
NO984418L true NO984418L (no) 1998-11-03

Family

ID=27486365

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984418A NO984418L (no) 1996-03-27 1998-09-22 Arylaminokondenserte pyridiner og pyrimidiner

Country Status (21)

Country Link
US (2) US6107300A (no)
EP (1) EP0935601A4 (no)
JP (1) JP2002515032A (no)
KR (1) KR20000005037A (no)
CN (1) CN1230184A (no)
AU (1) AU2545897A (no)
BR (1) BR9708261A (no)
CA (1) CA2250241A1 (no)
CZ (1) CZ304098A3 (no)
EA (1) EA199800868A1 (no)
EE (1) EE9800329A (no)
HR (1) HRP970173A2 (no)
HU (1) HUP9902340A3 (no)
IL (1) IL126316A0 (no)
LV (1) LV12262B (no)
NO (1) NO984418L (no)
NZ (1) NZ331874A (no)
PL (1) PL335258A1 (no)
SI (1) SI9720026A (no)
SK (1) SK131798A3 (no)
WO (1) WO1997035539A2 (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT874846E (pt) 1995-11-01 2003-08-29 Novartis Ag Derivados de purina e processos para a sua preparacao
EP0968210A1 (en) * 1997-03-21 2000-01-05 Du Pont Pharmaceuticals Company Method of making arylamino triazolopyridines
CA2296014A1 (en) * 1997-07-03 1999-01-14 Frank W. Hobbs Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
AU2881199A (en) * 1998-02-26 1999-09-15 Neurogen Corporation Substituted 1,4-dihydro-4-oxonicotinic carboxamides: gaba brain receptor ligands
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
DK1129096T3 (da) 1998-11-12 2003-09-15 Neurocrine Biosciences Inc CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
ES2180338T3 (es) 1998-11-12 2003-02-01 Neurocrine Biosciences Inc Antagonistas del receptor de crf y metodos relacionados.
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
OA12050A (en) 1999-09-30 2006-05-02 Neurogen Corp Certain alkylene diamine-substituted heterocycles.
US7115589B2 (en) * 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
AU2583901A (en) * 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
KR20030016222A (ko) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
US6589952B2 (en) 2000-07-14 2003-07-08 Bristol-Myers Squibb Pharma Company Imidazo[1,2-a]pyrazines for the treatment of neurological disorders
HU229604B1 (en) 2001-02-12 2014-02-28 Hoffmann La Roche 6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them
JP4549630B2 (ja) 2001-03-13 2010-09-22 ブリストル−マイヤーズ スクイブ ファーマ カンパニー コルチコトロピン放出因子受容体リガンドとしての、４−（２−ブチルアミノ）−２，７−ジメチル−８−（２−メチル−６−メトキシピリド−３−イル）ピラゾロ−［１，５−ａ］−１，３，５−トリアジン、その鏡像異性体および薬学的に許容できる塩類
US7205306B2 (en) 2001-05-14 2007-04-17 Bristol-Myers Squibb Pharma Company Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
AU2002354575A1 (en) 2001-07-12 2003-01-29 Bristol-Myers Squibb Pharma Company Tetrahydropurinones as corticotropin releasing factor
WO2003006015A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
GB0117525D0 (en) 2001-07-19 2001-09-12 Procter & Gamble Solvent welding process
GB0117522D0 (en) 2001-07-19 2001-09-12 Procter & Gamble Solvent welding process
AU2002340405A1 (en) 2001-11-20 2003-06-10 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
US9967633B1 (en) 2001-12-14 2018-05-08 At&T Intellectual Property I, L.P. System and method for utilizing television viewing patterns
WO2003051881A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
WO2005009348A2 (en) * 2003-06-25 2005-02-03 Ariad Pharmaceuticals, Inc. Substituted purine derivatives
MXPA06002618A (es) * 2003-09-09 2006-06-05 Ono Pharmaceutical Co Antagonistas del factor de liberacion de corticotropina (crf) y compuestos heterobiciclicos.
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
US20070197559A1 (en) * 2004-03-02 2007-08-23 Rajagopal Bakthavatchalam Aryl substituted purine analogues
EP1598354A1 (en) * 2004-05-18 2005-11-23 Vasopharm Biotech GmbH Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation
WO2006014325A2 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
CA2573538C (en) * 2004-07-30 2014-11-25 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
EP1846410B1 (en) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
EP1703668A1 (en) * 2005-03-18 2006-09-20 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO System for processing quality-of-service parameters in a communication network
JP5148499B2 (ja) * 2005-05-20 2013-02-20 メチルジーン インコーポレイテッド Ｖｅｇｆ受容体およびｈｇｆ受容体シグナル伝達の阻害剤
ES2473341T3 (es) * 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
JP2009502959A (ja) * 2005-07-28 2009-01-29 ブリストル−マイヤーズ スクイブ カンパニー セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
JP5015166B2 (ja) * 2005-11-08 2012-08-29 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕ５受容体アンタゴニストとしてのチアゾロ［４，５−ｃ］ピリジン誘導体
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
US20080004253A1 (en) * 2006-06-30 2008-01-03 Bryan James Branstetter Thiazolopyrimidine modulators of TRPV1
US7566722B2 (en) * 2006-10-31 2009-07-28 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
WO2008054796A2 (en) 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
NZ578096A (en) * 2007-01-10 2011-11-25 Albany Molecular Res Inc 5-pyridinone substituted indazoles
ES2382982T3 (es) * 2007-07-21 2012-06-15 Albany Molecular Research, Inc. Indazoles sustituidos con 5-piridinona y composiciones farmacéuticas de los mismos
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
WO2009109035A1 (en) * 2008-03-05 2009-09-11 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
EA038195B1 (ru) 2009-01-16 2021-07-22 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CN107709326B (zh) * 2015-02-18 2021-12-17 巴克老龄问题研究所 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶
CN108135907A (zh) 2015-08-21 2018-06-08 奥尔德拉医疗公司 氘化化合物和其用途
US11370793B2 (en) 2015-08-27 2022-06-28 Nantneuro, Llc Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
MX2020003425A (es) 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
CA3103048A1 (en) * 2018-06-21 2019-12-26 Janssen Pharmaceutica Nv Oga inhibitor compounds
EP3833660A4 (en) * 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
US4076711A (en) * 1976-04-05 1978-02-28 Schering Corporation Triazolo [4,5-d]-pyrimidines
EP0155911A1 (de) * 1984-03-19 1985-09-25 Ciba-Geigy Ag Purinderivate zur Regulierung des Pflanzenwachstums
GB8408615D0 (en) * 1984-04-04 1984-05-16 Wellcome Found Heterocyclic compounds
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US5175273A (en) * 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
US5240937A (en) * 1990-04-20 1993-08-31 Burroughs Wellcome Co. Pharmaceutically active triazolopyridine compounds
FI933303L (fi) * 1991-01-23 1993-08-31 Gensia Inc Adenosinkinasinhibitorer
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
DE69230803T2 (de) * 1991-11-25 2000-12-07 Pfizer Inc., New York 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
ATE178335T1 (de) * 1992-01-06 1999-04-15 Wellcome Found Therapeutische nukleoside der 2',3'-dideoxy-3'- fluor -purin reihe
US5424297A (en) * 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
KR100263429B1 (ko) * 1994-06-06 2000-08-01 디. 제이. 우드 코르티코트로핀-방출 인자(crf) 길항 활성을 갖는 치환된 피라졸
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
EP0765327B1 (en) * 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
JPH10506126A (ja) * 1995-05-12 1998-06-16 ニューロゲン コーポレイション 新規なデアザプリン誘導体；ｃｒｆ１特異性リガンドの新規なクラス
EP0778277B1 (en) * 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists

Also Published As

Publication number Publication date
EP0935601A4 (en) 2002-08-07
NO984418D0 (no) 1998-09-22
EP0935601A2 (en) 1999-08-18
JP2002515032A (ja) 2002-05-21
NZ331874A (en) 2000-03-27
SK131798A3 (en) 2000-05-16
CN1230184A (zh) 1999-09-29
LV12262B (en) 1999-10-20
CZ304098A3 (cs) 1999-02-17
IL126316A0 (en) 1999-05-09
WO1997035539A2 (en) 1997-10-02
LV12262A (lv) 1999-04-20
PL335258A1 (en) 2000-04-10
US6107300A (en) 2000-08-22
SI9720026A (sl) 1999-04-30
BR9708261A (pt) 2001-12-04
EE9800329A (et) 1999-06-15
AU2545897A (en) 1997-10-17
HUP9902340A3 (en) 2001-02-28
US6448261B1 (en) 2002-09-10
HRP970173A2 (en) 1999-08-31
HUP9902340A2 (hu) 1999-11-29
EA199800868A1 (ru) 1999-04-29
CA2250241A1 (en) 1997-10-02
KR20000005037A (ko) 2000-01-25
WO1997035539A3 (en) 1999-05-14

Similar Documents

Publication Publication Date Title
DK0901374T3 (da) Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
ATE194340T1 (de) Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
MY115300A (en) Pyrazolopyrimidines.
LV12262A (lv) Ar arilaminu kondenseti piridini un pirimidini
TW237455B (no)
PL293389A1 (en) Method of obtaining novel heterocyclic compounds
ATE264846T1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
HU9300898D0 (en) Non-aromatic heterocyclic compounds containing condensed nitrogenb
BG104597A (en) Inhibition of raf kinase using substituted heterocyclic ureas
TR199902357T2 (xx) Yeni bile�imler.
PT691128E (pt) Metodos de administracao de antagonistas de crf
ATE178886T1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
FI822281A0 (fi) Foerfarande foer framstaellning av pyrimidonderivat
NZ326675A (en) Oxazoline arthropodicides
TW366262B (en) Substituted pyridines/pyrimidines, their preparation, and their use as pesticides
ATE102626T1 (de) Heterocyclische verbindungen, ihre darstellung und verwendung.
BG103271A (en) Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means
NZ333229A (no)
SG95491G (en) 4-nitrogen substituted isoquinolinol compounds having cardiotonic,phosphodiesterase fraction iii inhibiting properties and/or renal vasodilating properties
ES8604853A1 (es) Un metodo para la preparacion de un derivado de acetileno.
ATE41662T1 (de) Derivate von dihydro-1h-pyrrolo(1,2-c>imidazol3,5-dion zur aktivierung des wahrnehmungsvermoegens.
DE59202242D1 (de) Ethanoladdukte von 6-sulfonylsubstituierten 3-Hydroxychromanen und ihre Verwendung als Inhalationsmittel bei Krankheiten.
DE69015411D1 (de) 5,11-Dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one und -thione und deren Verwendung bei der Vorbeugung und und Behandlung von AIDS.
EP0401049A3 (en) Beta-lactam elastase inhibitors
DK0609371T3 (da) Thienopyrazin-2,3-dioner og deres fremstilling og anvendelse